Emilia Arturo: Consider Submitting the Paper and Its Reviews for a Second Look Rapid Response From One of These Blood Journals
Emilia Arturo, Senior Managing Editor of Blood and Blood Global Hematology, reposted from Blood Journals Portfolio on LinkedIn:
”Have a paper already reviewed and rejected at another reputable hematology, immunology, or oncology journal?
Consider submitting the paper and its reviews for a Second Look Rapid Response from one of these Blood Journals!”
Quoting Blood Journals Portfolio‘s post:
”Submitting to a top medical journal can be a long process and not getting published can feel like a setback.
However, it doesn’t have to be the end of your manuscript’s journey.
The five specialized journals in the Blood Journals portfolio, Blood ICT, Blood RCI, Blood VTH, Blood Neoplasia, and Blood Global Hematology are offering authors a rapid second look.
If you have research within the scope of one of these journals, you could get published soon with the backing of the renowned Blood brand.
It’s simple:
- Update and submit a manuscript previously submitted to another reputable journal (with reviewer feedback)
- Receive an initial editorial assessment within just 3 business days
- Just 8 weeks from submission to publishing of first edition
Your work deserves to be seen. Learn more.”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia